Option chain shows key data for Mainz Biomed's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Mainz Biomed.

Mainz Biomed (NASDAQ:MYNZ) Stock, Option Chain

Mainz Biomed

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Screenshot 2024-12-19 at 7.13.05 PM

Biotech

General

MYNZ

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Man at computer, Business,Finance,Data,Analytics,Graph,Chart,Report,,Man,Using,Laptop

Large Cap

News

Health Care

Contracts

Stock Split

Movers

Trading Ideas

Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results.

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Mainz Biomed NV

WIIM

ECARX Holdings shares are trading higher after the company announced a plan to repurchase up to $20 million of its ordinary shares through September 30, 2025.

JP Morgan analyst Matthew Boss maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Overweight and raises the price target from $201 to $204.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Abercrombie & Fitch, Raises Price Target to $204

WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) has outperformed the market over the past 15 years by 31.59% on an annualized basis producing an average annual return of 43.27%. Currently, WEX has a market capitalization of $6.66 billion. 
Buying $1000 In WEX: If an investor had bought $1000 of WEX stock 15 years ago, it would be worth $219,844.16 today based on a price of $167.45 for WEX at the time of writing.
<h3>WEX's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711614_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

JP Morgan analyst Rajat Gupta maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Underweight and raises the price target from $70 to $72.

JP Morgan Maintains Underweight on CarMax, Raises Price Target to $72

TD Cowen analyst Daniel Chan upgrades BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) from Hold to Buy and raises the price target from $3.25 to $4.

Upgrades

TD Cowen Upgrades BlackBerry to Buy, Raises Price Target to $4

JP Morgan analyst Brian Ossenbeck maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Overweight and raises the price target from $366 to $370.

JP Morgan Maintains Overweight on FedEx, Raises Price Target to $370

Mastercard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) short percent of float has risen 5.48% since its last report. The company recently reported that it has 6.29 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mastercard Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711325_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mastercard has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Mastercard's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mastercard's peer group average for short interest as a percentage of float is 4.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Mastercard's Recent Short Interest

Viking Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NYSE">VKTX</a>) short percent of float has risen 6.35% since its last report. The company recently reported that it has 18.07 million shares sold short, which is 21.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Viking Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Viking Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Viking Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Viking Therapeutics's peer group average for short interest as a percentage of float is 13.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VKTX

Looking Into Viking Therapeutics's Recent Short Interest

Lumentum Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NYSE">LITE</a>) short percent of float has risen 5.18% since its last report. The company recently reported that it has 11.15 million shares sold short, which is 21.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lumentum Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734711315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lumentum Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lumentum Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lumentum Holdings's peer group average for short interest as a percentage of float is 6.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LITE

Peering Into Lumentum Holdings's Recent Short Interest

Macro Economic Events

Market Summary

Economics

Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher

DXCM

Shares of glucose monitoring stocks are trading higher following weaker-than-expected weight loss data from Novo Nordisk.

Pyxis Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) announced on Thursday, a portfolio prioritization, focusing resources on advancing its <a href="https://www.benzinga.com/pressreleases/24/12/g42603862/pyxis-oncology-announces-portfolio-prioritization-focusing-resources-on-its-lead-clinical-program-" target="_blank" rel="noreferrer noopener">lead clinical program, PYX-201</a>.
Pyxis Oncology&#8217;s second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201.
As a result, Pyxis Oncology has decided to suspend further clinical investment in PYX-106, which was in-licensed from Biosion Inc., with Biosion retaining rights for Greater China.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42113042/pyxis-oncologys-cancer-drug-progress-stirs-analyst-concerns" rel="noreferrer noopener">Pyxis Oncology&#8217;s Cancer Drug Progress Stirs Analyst Concerns</a>
In November, Pyxis Oncology reported preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
Among patients with HNSCC, PYX-201 achieved a confirmed 50% objective response rate (ORR), including one complete response and a disease control rate (DCR) of 100% in six heavily pretreated HPV-positive and HPV-negative evaluable patients with a median of four prior lines of therapy.
Across six solid tumor types of interest at therapeutically active dose levels, including HNSCC, ovarian, non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple-negative breast cancer (TNBC) and sarcoma, PYX-201 (n=31) achieved a 26% ORR in the Phase 1 trial, with dose-dependent responses observed.
The portfolio prioritization further supports a development plan for PYX-201 in several dose expansion studies, including monotherapy in 2/3L HNSCC, in combination with pembrolizumab in 1/2L+ HNSCC, and pembrolizumab combination studies in other solid tumors including HR+/HER2- and triple-negative breast cancer.
Preliminary data from these cohorts are expected in the second half of 2025 and the first half of 2026.
&#8220;Given the historical development challenges associated with anti-siglec-15 antibodies, we believe that the Street expectations were low heading into the initial data readout for PYX-106,&#8221; said the William Blair analyst.
The company&#8217;s current cash position is expected to fund its planned monotherapy and combination therapy trials of PYX-201 into the second half of 2026.
The analyst says it supports management's decision to stop investing in the program. While PYX-201 showed some activity, it likely won't significantly change head and neck cancer treatment.
PYXS Price Action: PYXS Oncology stock is up 1.30% at $1.56 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42615874/why-is-cancer-focused-aadi-bioscience-stock-trading-higher-on-friday" target="_blank" rel="noreferrer noopener">Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?</a></li>
</ul>
This image was created using artificial intelligence MidJourney.

Analyst Color

PYXS

Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move

SNPX

Synaptogenix shares are trading higher after the company announced it formed an independent Special Committee to explore strategic opportunities.

SCHL

Scholastic shares are trading lower after the company on Thursday reported worse-than-expected Q2 financial results.

BlackBerry shares are trading higher following Q3 financial results.

IONQ

IonQ shares are trading higher after Craig-Hallum raised its price target on the stock from $22 to $45 while maintaining a Buy rating.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

Reiteration

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Looking for <a href="https://www.benzinga.com/trading-ideas/dividends">steady cash flow</a> in 2025? JPMorgan analysts have spotlighted four income-generating stock picks that offer dividend appeal and potential price upside. 
These are: Annaly Capital Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>), Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>), Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and HA Sustainable Infrastructure Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>).
Here are the details on their top picks.
<h2 class="wp-block-heading">Annaly Capital</h2>
With a hefty forward dividend yield of 13.85% (per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), Annaly Capital shines as a beacon for income seekers. 
Analyst Richard Shane expects the mortgage REIT to benefit from a gradual yield curve steepening and rising MBS prices as quantitative tightening eases. 
Trading near $19.76, NLY is viewed as a stable dividend play, supported by mid-teen ROEs and rising interest spreads, according to the analyst. His price target for 2025 is $20.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42615289/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks Delivering High-Dividend Yields</a>
<h2 class="wp-block-heading">Corning</h2>
Known for its innovation in glass and fiber optics, Corning offers more than shiny screens. 
Its modest 2.38% yield may seem subdued, but JPMorgan's Samik Chatterjee says this tech titan is poised for high-single-digit revenue growth. 
Riding on data center demand, telecom recovery, and AI-driven innovation, Corning's stock—currently at $48.18—has room to climb to $60 by the end of 2025, the analyst says.
<h2 class="wp-block-heading">Energy Transfer</h2>
Pipeline powerhouse Energy Transfer is turning heads with a forward dividend yield of 7.06%. 
Analyst Jeremy Tonet sees untapped value in its discounted EV/EBITDA ratio compared to peers. 
With fundamentals like Permian egress and natgas logistics firing on all cylinders, ET, trading at $18.70, appears poised to reach Tonet's $23 target, presenting a compelling opportunity for midstream investors.
<h2 class="wp-block-heading">HASI</h2>
Sustainability meets income in Hannon Armstrong Sustainable Infrastructure Capital. HASI's 6.29% yield sweetens the deal for this eco-friendly investment.
JPMorgan's Mark Strouse predicts a brighter outlook thanks to its KKR partnership and investment-grade rating. With shares at $28.72, Strouse forecasts a $42 price by 2025 as HASI reduces its reliance on public capital raises and executes on stable spreads.
Whether you're chasing high yields or balanced growth, these four income plays could be the backbone of your 2025 portfolio. 
From Annaly's robust dividends to Corning's AI-driven potential, JPMorgan's picks are all about turning steady streams into rivers of returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42612794/djt-stock-plummets-over-5-following-trumps-stake-transfer-heres-more">DJT Stock Plummets Over 5% Following Trump&#8217;s Stake Transfer: Here&#8217;s More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

REIT

Dividends

Real Estate

Hannon Armstrong Sustainable Infrastructure Capital

HASI

4 Dividend Picks For 2025: JPMorgan's Top Income Stocks To Energize Your Portfolio

BCAB

BioAlta shares are trading lower after the company announced a $9.2 million registered direct offering of 9,679,158 shares at $1.19 per share.

Jefferies analyst Surinder Thind maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Hold and raises the price target from $355 to $385.

Jefferies Maintains Hold on Accenture, Raises Price Target to $385

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more… The increase in the number of elderly people, faster economic growth, technological advancements, changes in lifestyles, and enhanced ability to survive and standard of living are expected to contribute to the growth of the healthcare services Market.
Given this backdrop, it could be wise to consider investing in fundamentally strong healthcare stocks, Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>), Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>), and Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>) for a healthy portfolio in 2025.
The healthcare industry is experiencing significant growth, driven by rapid technological advancements that enhance efficiency and accessibility, as well as a surge in partnerships fostering innovation and the development of solutions.
Ongoing progress in pharmaceuticals and medical technologies continues to propel the sector forward, with global pharmaceutical revenues expected to hit $1.16 trillion this year and grow at a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">CAGR of 6.2%</a>, reaching $1.47 trillion by 2028.
Diagnostics also plays a crucial role, which is why the global clinical diagnostics market is worth $86.72 billion in 2024 and is projected to <a href="https://www.biospace.com/clinical-diagnostics-market-size-to-hit-usd-140-53-billion-by-2033">expand at a CAGR of 5.5%</a> by 2033.
Given these favorable industry trends, let's look at the fundamentals of three healthcare stocks.
Eli Lilly and Company (<a href="https://stocknews.com/stock/LLY/">LLY</a>)
LLY discovers, develops, and markets human pharmaceuticals worldwide. The company offers medicines for diabetes, obesity, and other cardiometabolisms.
On December 5, 2024, LLY announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing facility that the company acquired earlier this year.
This investment would extend the company's global parenteral (injectable) product manufacturing network, helping meet the growing demand for diabetes, obesity, and future pipeline medicines across therapeutic areas.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a>, LLY's 40.54% is 626.1% higher than the 5.58% industry average. Likewise, its 11.34% trailing-12-month CAPEX/ Sales is 260.6% higher than the 3.14% industry average. Its 36.46% trailing-12-month EBIT margin is considerably higher than the 2.54% industry average.
During the third quarter ended September 30, 2024, LLY's revenue increased by 20% year-over-year to $11.44 billion. The company's non-GAAP net income was $1.06 billion, or $1.18 per share, up considerably year-over-year.
The consensus revenue estimate of $14 billion for the fiscal fourth quarter (ending December 2024) represents a 49.7% increase year-over-year. The company expects its EPS to increase 118.5% year-over-year to $5.44. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in three of the trailing four quarters.
Over the past year, the stock has surged 34.4%, closing the last trading session at $803.58.
LLY's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
LLY has a B grade for Sentiment and Growth. It is ranked #30 out of 155 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/LLY/">Click here</a> to see the additional ratings for LLY (Value, Momentum, Quality, and Stability).
Thermo Fisher Scientific Inc. (<a href="https://stocknews.com/stock/TMO/">TMO</a>)
TMO is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies globally. It operates through four segments: Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.
On November 12, 2024, TMO announced a collaborative agreement with Mainz Biomed N.V. (<a href="https://stocknews.com/stock/MYNZ/">MYNZ</a>), a molecular genetics diagnostic company specializing in early cancer detection.
The collaboration agreement would enable MYNZ and TMO to jointly develop and potentially commercialize Mainz Biomed's Next Generation colorectal cancer screening product. 
In terms of the trailing-12-month levered FCF margin, TMO's 16.01% is 610.6% higher than the 2.25% industry average. Its 0.43x trailing-12-month asset turnover ratio is 4.4% higher than the 0.41x industry average. Similarly, the stock's 17.42% trailing-12-month EBIT margin is 595.5% higher than the 2.51% industry average.
For the third quarter of 2024, which ended on September 28, 2024, TMO's revenue increased marginally year-over-year to $10.60 billion. Its adjusted net income for the quarter amounted to $2.03 billion, while its adjusted EPS stood at $5.28.
Street expects TMO's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 3.8% and 5% year-over-year to $11.30 billion and $4.95, respectively. Moreover, it beat the revenue estimates in each of the trailing four quarters, which is promising.
Shares of TMO have gained 9.7% over the past year to close the last trading session at $537.23.
TMO's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
TMO has a B grade for Sentiment and Stability. It is ranked #4 out of 41 stocks in the <a href="https://stocknews.com/category/medical-diagnostics-research/">Medical - Diagnostics/Research</a> industry.
In addition to the POWR Ratings we've stated above, we also have TMO ratings for Momentum, Growth, Value, and Quality. Get all TMO ratings <a href="https://stocknews.com/stock/TMO/">here</a>.
Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells healthcare products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
On November 25, 2024, ABT announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward ABT's software-guided balloon-expandable TAVI system and is designed to build a foundation for AI-guided procedures. 
In terms of the trailing-12-month levered FCF margin, ABT's 15.54% is 589.8% higher than the 2.25% industry average. Its 0.56x trailing-12-month asset turnover ratio is 36.9% higher than the 0.41x industry average. Similarly, the stock's 18.44% trailing-12-month EBIT margin is 636.2% higher than the 2.51% industry average.
For the third quarter that ended on September 30, 2024, ABT's net sales rose 4.9% year-over-year to $20.34 billion. Its operating earnings grew 12.8% from the year-ago value to $1.86 billion. In addition, the company's adjusted net earnings stood at $2.12 billion, or $0.94 per share.
The consensus revenue estimate of $11.04 billion for the fiscal fourth quarter (ending December 2024) represents a 7.8% increase year-over-year. The consensus EPS estimate of $1.34 for the same quarter indicates a 12.8% improvement year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
Over the past six months, the stock has surged 6.8%, closing the last trading session at $114.90.
ABT's POWR Ratings reflect its bright outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
ABT has a B grade for Stability and Sentiment. It is ranked #13 out of 138 stocks in the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical - Devices &amp; Equipment</a> industry. <a href="https://stocknews.com/stock/ABT/">Click here</a> to see the additional ratings for ABT (Growth, Value, Momentum, and Quality).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
LLY shares were trading at $801.78 per share on Tuesday afternoon, down $1.80 (-0.22%). Year-to-date, LLY has gained 38.44%, versus a 28.32% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/lly-tmo-abt-mynz-3-healthcare-stocks-to-buy-now-for-a-healthy-portfolio/>3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025

Mainz Biomed prices $8M offering of shares and warrants

Maxim Group LLC is acting as the sole placement agent for the offering. Published first on TheFly – the ultimate source for real-time, market-movin...

Mainz Biomed prices $8.0M at-the-market offering at $5.85 per unit

Mainz Biomed B.V. ( ($MYNZ) ) has provided an announcement. Mainz Biomed announced the pricing of an $8 million follow-on offering, with each unit ...

Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations

09:33 EST Mainz Biomed (MYNZ) NV trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mov...

Mainz Biomed NV trading halted, volatility trading pause

09:43 EST Mainz Biomed (MYNZ) NV trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

Mainz Biomed NV trading resumes

Mainz Biomed B.V. ( ($MYNZ) ) has provided an announcement. Mainz Biomed has successfully closed an $8 million follow-on offering, selling 1,367,52...

Mainz Biomed Secures $8 Million in Follow-On Offering

Mainz Biomed (MYNZ) announced an agreement with Quest Diagnostics (DGX), a leading provider of diagnostic information services, to support commerci...

Mainz Biomed forms agreement with Quest Diagnostics

Quest Diagnostics deal sends Mainz higher

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Screenshot 2024-11-11 at 7.48.49 PM

What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer

Screenshot 2024-10-04 at 11.57.48 PM

Interview

Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early

Screenshot 2024-09-04 at 5.52.15 PM

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Screenshot 2024-08-30 at 2.55.26 PM

Emerging Markets

Markets

Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test

Screenshot 2024-08-30 at 6.27.59 PM

EXAS

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-07-30 at 7.23.29 PM

Mainz Biomed&#39;s (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Earnings

Press Releases

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

Mainz Biomed Announces Stock Split

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Comments

Mainz Biomed

Mainz Biomed (MYNZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga